RESUMEN
BACKGROUND: One of the most challenging conditions in Crohn's disease (CD) patients is the treatment of perianal fistulae. We have recently shown that epithelial-to-mesenchymal transition (EMT) plays a crucial role during CD-fistulae development. Dickkopf-homolog 1 (DKK-1) is known to play a key role during EMT. Here, we investigated a role for DKK-1 in the pathogenesis of CD-associated fistulae. METHODS: Dkk-1 protein expression in CD-fistula specimens were investigated by immunohistochemistry. Colonic lamina propria fibroblasts (CLPF) were obtained from either non-IBD control patients or patients with fistulizing CD. HT-29 intestinal epithelial cells (IEC) were either grown as monolayers or spheroids. Cells were treated with either TNF-α, TGF-ß or IL-13. Knock-down of DKK-1 or ß-Catenin was induced in HT-29-IEC by siRNA technique. mRNA expression was determined by real-time-PCR. RESULTS: Dkk-1 protein was specifically expressed in transitional cells lining the fistula tracts. TGF-ß induced DKK-1 mRNA expression in HT-29-IEC, but decreased it in fistula CLPF. On a functional level, DKK-1 knock-down prevented TGF-ß-induced IL-13 mRNA expression in HT-29-IEC. Further, loss of ß-Catenin was accompanied by reduced levels of DKK-1 and, again, IL-13 in IEC in response to TGF-ß. In turn, treatment of HT-29-IEC as well as fistula CLPF with IL-13 resulted in decreased levels of DKK-1 mRNA. Treatment with TNF-α or the bacterial wall component, muramyl-dipeptide, decreased DKK-1 mRNA levels in HT-29-IEC, but enhanced it in fistula CLPF. DISCUSSION: We demonstrate that DKK-1 is strongly expressed in cells lining the CD-fistula tracts and regulates factors involved in EMT initiation. These data provide evidence for a role of DKK-1 in the pathogenesis of CD-associated perianal fistulae.
Asunto(s)
Enfermedad de Crohn/metabolismo , Fístula/metabolismo , Péptidos y Proteínas de Señalización Intercelular/genética , Enfermedad de Crohn/complicaciones , Enfermedad de Crohn/genética , Células Epiteliales/metabolismo , Células Epiteliales/patología , Transición Epitelial-Mesenquimal , Fibroblastos/metabolismo , Fístula/complicaciones , Fístula/genética , Técnicas de Silenciamiento del Gen , Células HT29 , Humanos , Péptidos y Proteínas de Señalización Intercelular/biosíntesis , Membrana Mucosa/metabolismo , Membrana Mucosa/patología , ARN Mensajero/biosíntesis , Factor de Necrosis Tumoral alfa/administración & dosificaciónRESUMEN
OBJECTIVE: Epithelial to mesenchymal transition (EMT) seems to play an important role in the pathogenesis of fistulae, a common clinical complication of Crohn's disease (CD). TGFß and interleukin-13 (IL-13) have been correlated with the onset of EMT-associated organ fibrosis and high levels of TGFß have been shown in transitional cells (TCs) lining CD fistula tracts. This study investigated whether IL-13 could be involved in the pathogenesis of CD-associated fistulae. DESIGN: Protein or mRNA levels in HT29 intestinal epithelial cells (IECs) or colonic lamina propria fibroblasts (CLPFs) were studied by western blotting or real-time PCR. CLPFs were isolated from non-inflammatory disease controls or patients with CD with or without fistulae and IL-13 levels were analysed in surgically removed fistula specimens by immunohistochemistry. RESULTS: TGFß induced IL-13 secretion in CLPFs from patients with fistulising CD. In fistula specimens high levels of IL-13 were detected in TCs covering fistula tracts. In HT29 IEC monolayers, IL-13 induced SLUG and ß6-integrin mRNA, which are associated with cell invasion. HT29 spheroids completely disintegrated when treated with TGFß for 7 days, whereas IL-13-treated spheroids did not show morphological changes. Here, TGFß induced mRNA expression of SNAIL1 and IL-13, whereas IL-13 elevated SLUG and ß6-integrin mRNA. An anti-IL-13 antibody was able to prevent IL-13-induced SLUG expression in HT29 IECs. CONCLUSIONS: TGFß induces IL-13 expression and an EMT-like phenotype of IECs, while IL-13 promotes the expression of genes associated with cell invasion. These findings suggest that TGFß and IL-13 play a synergistic role in the pathogenesis of fistulae and inhibition of IL-13 might represent a novel therapeutic approach for fistula treatment.
Asunto(s)
Enfermedad de Crohn/complicaciones , Interleucina-13/metabolismo , Fístula Intestinal/etiología , Mucosa Intestinal/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Adulto , Biomarcadores/metabolismo , Western Blotting , Estudios de Casos y Controles , Colitis Ulcerosa/metabolismo , Enfermedad de Crohn/metabolismo , Enfermedad de Crohn/patología , Femenino , Fibroblastos/metabolismo , Fibroblastos/patología , Células HT29 , Humanos , Cadenas beta de Integrinas/metabolismo , Fístula Intestinal/metabolismo , Fístula Intestinal/patología , Mucosa Intestinal/patología , Masculino , Persona de Mediana Edad , Reacción en Cadena en Tiempo Real de la Polimerasa , Factores de Transcripción de la Familia Snail , Factores de Transcripción/metabolismoRESUMEN
BACKGROUND: The motivation of patients with functional gastrointestinal disorders to accept psychotherapy (PT) as a treatment option is not known. OBJECTIVE: The authors investigated motivation for patients' refusal to participate and dropout from PT/medical management programs. METHOD: Consecutive patients with symptoms suggestive of functional bowel disorders, seen at the outpatient clinic of a tertiary gastrointestinal (GI) center were evaluated for their motivation to undergo PT. Data from 85 patients were evaluated in two phases: In Phase 1, patients were asked about willingness to participate in PT if it were offered; in Phase 2, patients were offered PT. In both samples, PT motivation was also measured by standardized psychometric scales. RESULTS: Age, gender, social status, and clinical symptom severity did not predict willingness to participate in or accept PT. Motivation was higher when patients were directly recruited in a GI setting than a psychosomatic outpatient unit. Quantitative assessment of PT motivation also did not correlate with declared PT motivation or participation. Assessment of interpersonal problems were among the few variables that were related to participation in PT. CONCLUSION: Motivation for PT in patients with functional gastrointestinal disorders is low and is not determined by clinical, but, rather, by interpersonal problems that may exist beyond and independent of GI symptoms.
Asunto(s)
Enfermedades Gastrointestinales/psicología , Motivación , Pacientes Desistentes del Tratamiento/psicología , Trastornos Psicofisiológicos/psicología , Psicoterapia de Grupo , Trastornos Somatomorfos/psicología , Negativa del Paciente al Tratamiento/psicología , Adulto , Terapia Combinada , Femenino , Enfermedades Gastrointestinales/diagnóstico , Enfermedades Gastrointestinales/terapia , Alemania , Humanos , Masculino , Persona de Mediana Edad , Aceptación de la Atención de Salud/psicología , Inventario de Personalidad , Trastornos Psicofisiológicos/diagnóstico , Trastornos Psicofisiológicos/terapia , Derivación y Consulta , Trastornos Somatomorfos/diagnóstico , Trastornos Somatomorfos/terapiaRESUMEN
Quantitative changes of enteric glia (EGC) have been implicated in gastrointestinal disorders. To facilitate future studies of EGC in human pathology, we aimed to characterize thoroughly glial markers in the human enteric nervous system (ENS) and to compare EGC in man and guinea pig. Whole-mount preparations of the enteric nerve plexuses from human and guinea pig ileum and colon were labeled with antibodies against S100b, glial fibrillary acidic protein (GFAP), and p75NGFR and the transcription factors Sox8/9/10 and neuronally counterstained. Abundant immunoreactivity (IR) for S100b, GFAP, p75NGFR, and Sox8/9/10 was detected in EGC of all studied regions. Although the cytoplasmatic staining pattern of most markers did not permit glial quantification, the nuclear localization of Sox8/9/10-IR allowed to identify and count all EGC individually. In both man and guinea pig, myenteric ganglia were larger and contained more EGC and neurons than submucous ganglia. Furthermore, there were more EGC in the human than in the guinea pig myenteric plexus (MP), glial density was consistently higher in the human ENS, and the glia index (glia:neuron ratio) ranged from 1.3 to 1.9 and from 5.9 to 7.0 in the human submucous plexus (SMP) and MP, respectively, whereas, in guinea pig, the glia index was 0.8-1.0 in the SMP and 1.7 in the MP. The glia index was the most robust quantitative descriptor within one species. This is a comprehensive set of quantitative EGC measures in man and guinea pig that provides a basis for pathological assessment of glial proliferation and/or degeneration in the diseased gut.
Asunto(s)
Proteínas de Unión al ADN/fisiología , Sistema Nervioso Entérico/fisiología , Proteínas del Grupo de Alta Movilidad/fisiología , Neuroglía/fisiología , Factores de Transcripción/fisiología , Adolescente , Animales , Anticuerpos , Anticuerpos Monoclonales , Colon/inervación , Colon/patología , Sistema Nervioso Entérico/citología , Sistema Nervioso Entérico/patología , Femenino , Cobayas , Humanos , Íleon/inervación , Íleon/patología , Neoplasias Intestinales/patología , Neoplasias Intestinales/cirugía , Masculino , Neuroglía/citología , Factor de Transcripción SOX9 , Factores de Transcripción SOXE , Especificidad de la EspecieRESUMEN
BACKGROUND & AIMS: Barrier functions across epithelia and endothelia are essential for homeostatic tissue regulation. Astroglia interact with cerebral endothelia to maintain the blood-brain barrier. Whether similar interactions between astrocyte-like enteric glia and epithelia regulate intestinal barrier function is not known. METHODS: Fluorescent permeability markers were used to measure intestinal barrier function in vivo after conditional ablation of enteric glia in transgenic mice. Enteric glial cell regulation of epithelial barrier integrity then was modeled in vitro using coculture. Glial-derived barrier-inducing factors were characterized using size-exclusion chromatography and mass spectrometry. Epithelial barrier integrity was assessed by transepithelial resistance readings and by quantitative measurement of tight-junction-associated protein expression by quantitative polymerase chain reaction and Western blot. RESULTS: We show that ablation of enteric glial cells in transgenic mice causes intestinal mucosal barrier dysfunction, resulting in inflammation. Glial-derived s-nitrosoglutathione (GSNO) was identified as a potent inducer of mucosal barrier function in vitro and in vivo and of attenuated tissue inflammation after ablation of enteric glia in transgenic mice. GSNO regulation of mucosal barrier function was associated directly with an increased expression of perijunctional F-actin and tight-junction-associated proteins zonula occludens-1 and occludin. GSNO also significantly restored mucosal barrier function in colonic biopsy specimens from patients with Crohn's disease, a well-described inflammatory permeability disorder associated with enteric glial-cell disruption. CONCLUSIONS: Enteric glia therefore share the ability of astrocytes to regulate tight-junction integrity, and cellular interactions comparable with those maintaining blood-brain barrier function also regulate epithelial permeability at mucosal surfaces.
Asunto(s)
Astrocitos/fisiología , Colitis/metabolismo , Sistema Nervioso Entérico/fisiología , Mucosa Intestinal , S-Nitrosoglutatión/metabolismo , Actinas/genética , Adolescente , Adulto , Anciano , Animales , Biopsia , Western Blotting , Células Cultivadas , Colitis/patología , Colitis/fisiopatología , Colon/metabolismo , Colon/patología , Dextranos/farmacocinética , Perros , Combinación de Medicamentos , Sistema Nervioso Entérico/cirugía , Ensayo de Inmunoadsorción Enzimática , Epitelio/metabolismo , Estradiol/análogos & derivados , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Expresión Génica , Humanos , Mucosa Intestinal/citología , Mucosa Intestinal/inervación , Mucosa Intestinal/metabolismo , Proteínas de la Membrana/genética , Ratones , Ratones Transgénicos , Persona de Mediana Edad , Noretindrona , Ocludina , Permeabilidad , Reacción en Cadena de la Polimerasa , ARN/genética , Ratas , Testosterona/análogos & derivados , Proteína de la Zonula Occludens-2RESUMEN
The role of enteric glia in gastrointestinal physiology remains largely unexplored. We examined the actions of the gliotoxin fluorocitrate (FC) on intestinal motility, secretion, and inflammation after assessing its efficacy and specificity in vitro. FC (100 microM) caused a significant decrease in the phosphorylation of the glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diaz-4-yl)amino]-2-deoxyglucose in enteric glial cultures and a reduction in glial uptake of the fluorescent dipeptide Ala-Lys-7-amino-4-methylcoumarin-3-acetic acid in both the ileum and colon. Dipeptide uptake by resident murine macrophages or guinea pig myenteric neurons was unaffected by FC. Incubation of isolated guinea pig ileal segments with FC caused a specific and significant increase in glial expression of the phosphorylated form of ERK-1/2. Disruption of enteric glial function with FC in mice reduced small intestinal motility in vitro, including a significant decrease in basal tone and the amplitude of contractility in response to electrical field stimulation. Mice treated with 10 or 20 micromol/kg FC twice daily for 7 days demonstrated a concentration-dependent decrease in small intestinal transit. In contrast, no changes in colonic transit or ion transport in vitro were observed. There were no changes in glial or neuronal morphology, any signs of inflammation in the FC-treated mice, or any change in the number of myenteric nitric oxide synthase-expressing neurons. We conclude that FC treatment causes enteric glial dysfunction, without causing intestinal inflammation. Our data suggest that enteric glia are involved in the modulation of enteric neural circuits underlying the regulation of intestinal motility.
Asunto(s)
Citratos/toxicidad , Sistema Nervioso Entérico/efectos de los fármacos , Enfermedades Gastrointestinales/inducido químicamente , Motilidad Gastrointestinal/fisiología , Intestinos/citología , Intestinos/fisiología , Neuroglía/fisiología , 4-Cloro-7-nitrobenzofurazano/análogos & derivados , 4-Cloro-7-nitrobenzofurazano/farmacología , Animales , Células Cultivadas , Colitis/inducido químicamente , Desoxiglucosa/análogos & derivados , Desoxiglucosa/farmacología , Sistema Nervioso Entérico/citología , Enfermedades Gastrointestinales/patología , Motilidad Gastrointestinal/efectos de los fármacos , Tránsito Gastrointestinal/efectos de los fármacos , Procesamiento de Imagen Asistido por Computador , Inmunohistoquímica , Masculino , Ratones , Ratones Endogámicos C57BL , Contracción Muscular/efectos de los fármacos , Neuroglía/efectos de los fármacos , Neuronas/enzimología , Óxido Nítrico Sintasa de Tipo III/biosíntesis , Óxido Nítrico Sintasa de Tipo III/genética , Ratas , Ratas Sprague-DawleyRESUMEN
The peptide transporter PEPT2 mediates transmembrane uptake of small peptides. So far, its expression has not been evidenced in the gastrointestinal tract. We have investigated peptide transport activity in the neuromuscular layers of the gastrointestinal tract by using the fluorescent tracer-dipeptide beta-Ala-Lys-Nepsilon-7-amino-4-methyl-coumarin-3-acetic acid (Ala-Lys-AMCA). Whole-mount preparations from mouse, rat, and guinea pig stomach and small and large intestine were incubated with Ala-Lys-AMCA in the presence or absence of the uptake-inhibitors L-histidine, D-phenylalanyl-L-alanine (D-Phe-Ala), glycyl-L-sarcosine (Gly-Sar), glycyl-L-glutamine (Gly-Gln), benzylpenicillin, and cefadroxil. Fluorescence microscopy revealed that Ala-Lys-AMCA specifically accumulated in both ganglionic layers of the enteric nervous system (ENS) in all regions and species studied. This could be inhibited by Gly-Sar, D-Phe-Ala, Gly-Gln, and cefadroxil, but not by free histidine and benzylpenicillin, indicating uptake via PEPT2. Accordingly, dipeptide uptake was completely abolished in PEPT2-deficient mice. Reverse transcriptase-polymerase chain reaction analysis detected a PEPT2-specific transcript in extracts from the ganglionic ENS layers of mouse small and large intestine, further proving that enteric dipeptide transport activity is specifically mediated via PEPT2. The cellular site of dipeptide uptake was immunohistochemically localized to enteric glial cells and tissue-resident macrophages. In addition, dipeptide uptake occurred in a neurochemically defined subset of neurons in the guinea pig ENS. Our results constitute the first functional evidence for dipeptide transport activity in the ENS. PEPT2-mediated dipeptide transport in enteric glia could contribute to the clearance of neuropeptides in the ENS. In addition, the fluorophore-coupled dipeptide uptake via PEPT2 is a novel vital marker for glial cells in the ENS.
Asunto(s)
Sistema Nervioso Entérico/metabolismo , Regulación de la Expresión Génica/fisiología , Simportadores/metabolismo , Animales , Animales Modificados Genéticamente , Antígenos de Diferenciación/metabolismo , Transporte Biológico/efectos de los fármacos , Transporte Biológico/fisiología , Northern Blotting/métodos , Calbindinas , Recuento de Células/métodos , Colina O-Acetiltransferasa/metabolismo , Cumarinas/farmacocinética , Dipéptidos/farmacocinética , Dipéptidos/farmacología , Proteínas ELAV , Proteína 3 Similar a ELAV , Sistema Nervioso Entérico/citología , Sistema Nervioso Entérico/efectos de los fármacos , Proteína Ácida Fibrilar de la Glía/metabolismo , Cobayas , Histidina/farmacología , Inmunohistoquímica/métodos , Técnicas In Vitro , Mamíferos , Ratones , Ratones Endogámicos C57BL , Proteínas del Tejido Nervioso , Neuronas/metabolismo , Fosfopiruvato Hidratasa/metabolismo , Canales de Potasio Calcio-Activados/metabolismo , ARN Mensajero/biosíntesis , Proteínas de Unión al ARN , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Proteína G de Unión al Calcio S100/metabolismo , Proteínas S100/metabolismo , Canales de Potasio de Pequeña Conductancia Activados por el Calcio , Simportadores/deficiencia , Simportadores/genéticaRESUMEN
UNLABELLED: We evaluated quantitative measurement series (MS) with 18F-FDG and PET and compared different quantification methods for prediction of individual survival in patients with metastatic colorectal cancer receiving chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX). METHODS: The study comprised 25 patients. All patients were examined before the onset of FOLFOX therapy and after completion of the first and fourth cycles. SUV, fractal dimension (FD), a 2-compartment model with computation of k1, k2, k3, and k4, and vascular fraction (VB) were used for data evaluation. Survival data served as a reference for the PET data. Discriminant analysis (DA), regression, and best-subset analysis were applied to the data. RESULTS: Twenty of 25 patients died up to 801 d after the first PET study. A cutoff of 1 y (364 d) was used to classify the patients into 2 a priori groups, namely the short- and long-term survival groups. DA was used to predict the 2 categories using SUV and kinetic parameters of 18F-FDG metabolism as predictor variables. SUV provided a correct classification rate (CCR) ranging from 62% to 69%. SUV of the third MS resulted in a CCR of 69% as a single parameter. The best results were yielded by the use of kinetic parameters (k1, k3, VB, and FD) as predictor variables. CCR was 78% using kinetic 18F-FDG parameters of the first and third MS, in comparison with 69% for the corresponding SUVs. A multiple linear regression model was applied to the data to assess the relationship between individual survival and the PET data. The best-subset method revealed a correlation coefficient of 0.850 for the kinetic parameters of the first (k3, k4, VB, and FD) and third (k1, k2, k4, and VB) MS. CONCLUSION: The combination of kinetic parameters of the first and the third MS is acceptable for classification into a short or long survival class. Furthermore, even an individual prognosis of survival can be achieved using kinetic 18F-FDG parameters of the first and third MS.